Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition

The new Board will have several standing committees, including Audit and Compliance, Compensation, Nominating and Corporate Governance and Operations and Innovation.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

SOURCE Actavis plc